Eliquis (Apixaban) belongs to the group of direct-acting oral anticoagulants and has an antithrombotic effect. It is used for atrial fibrillation and flutter, strokes, emboli and venous thrombosis, as well as for complications associated with internal orthopedic prosthetic devices, implants and transplants. The effect is achieved due to the fact that apixaban is a powerful direct FXa inhibitor that reversibly and selectively blocks the active center of the enzyme. To implement the antithrombotic activity of apixaban, the presence of antithrombin III is not required. Apixaban inhibits free and bound FXa, as well as prothrombinase activity. Apixaban does not directly affect platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin.
The total duration of therapy should be selected individually after a careful assessment of the correlation between the benefits of taking the drug and the risk of bleeding.
In case of a missed intake, the drug should be taken as soon as possible, and then continue to take 2 times a day in accordance with the original scheme.
For patients who cannot swallow the whole tablet, Eliquis (Apixaban) tablet can be crushed and diluted in water or 5% aqueous dextrose or apple juice and given to the patient for immediate oral administration.
- skin itch
- skin rash
- bleeding, hematomas
- nose bleeding
- arterial hypotension
The use of Eliquis (Apixaban) may be associated with an increased risk of bleeding (including hidden) from any organ or tissue, which, in turn, can lead to the development of posthemorrhagic anemia.
Symptoms, signs and severity will vary depending on the source of bleeding and the degree or prevalence of bleeding. Contact your doctor immediately if you experience any serious or worrying symptoms.
Information on excipients. Eliquis (Apixaban) contains lactose. Patients with rare hereditary disorders such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption should not take Eliquis (Apixaban).